Who are Duragesic's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sevoflurane and Remifentanil, Tramal®, Tramadol HCl, Tramadol 50.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fentanyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Duragesic — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Duragesic (fentanyl) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic opioid analgesic. Area: Oncology.

marketed Synthetic opioid analgesic D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Duragesic (fentanyl) — Johnson & Johnson (Janssen Pharmaceutica). Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Duragesic TARGET	fentanyl	Johnson & Johnson (Janssen Pharmaceutica)	marketed	Synthetic opioid analgesic	D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor	1968-01-01
Sevoflurane and Remifentanil	Sevoflurane and Remifentanil	University General Hospital of Patras	marketed	General anesthetic (sevoflurane) and synthetic opioid analgesic (remifentanil)	GABA receptors (sevoflurane); mu-opioid receptor (remifentanil)
Tramal®	Tramal®	Apsen Farmaceutica S.A.	marketed	Synthetic opioid analgesic	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol HCl	Tramadol HCl	Labopharm Inc.	marketed	Synthetic opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol 50	Tramadol 50	Grünenthal GmbH	phase 3	Synthetic opioid analgesic	Mu opioid receptor; norepinephrine transporter; serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-01-25 — Duragesic · 10016403 · Formulation · US
2027-01-25 — Duragesic · 8835460 · Formulation · US
2027-01-25 — Duragesic · 9642797 · Formulation · US
2027-01-25 — Duragesic · 9289387 · Formulation · US
2027-01-25 — Duragesic · 8835459 · Formulation · US
2027-01-25 — Duragesic · 10610523 · Formulation · US
2027-01-25 — Duragesic · 9241935 · Formulation · US
2027-01-25 — Duragesic · 9642844 · Formulation · US
2030-04-27 — Duragesic · 8486972 · Formulation · US
2030-04-27 — Duragesic · 8486973 · Method of Use · US

Sponsor landscape (Synthetic opioid analgesic class)

Apsen Farmaceutica S.A. · 1 drug in this class
Grünenthal GmbH · 1 drug in this class
Johnson & Johnson (Janssen Pharmaceutica) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Duragesic — Competitive Intelligence Brief. https://druglandscape.com/ci/fentanyl. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing